Clinical Pharmacology & Biopharmaceutics
Open Access

Bioavailability; Biopharmaceutics; Solubility enhancement; Permeability enhancement; Drug formulation; Solid dispersions; Lipid-based formulations; Nanotechnology; Prodrugs; Cyclodextrins; Enzyme inhibitors

Introduction

Bioavailability is a critical factor in drug development, determining the fraction of an administered dose that reaches the systemic circulation and is available for therapeutic action. In biopharmaceutics, enhancing bioavailability can improve drug efficacy, reduce dosage frequency, and minimize side effects. Various strategies have been developed to address poor bioavailability, especially for drugs with low solubility and permeability [1].

Factors affecting bioavailability

Solubility: Poor water solubility can limit the dissolution of a drug, thereby reducing its bioavailability.

Permeability: Drugs must traverse biological membranes to reach the bloodstream. Low membrane permeability can hinder this process.

First-Pass Metabolism: Drugs metabolized extensively in the liver or intestine before reaching systemic circulation can have reduced bioavailability.

Drug Stability: Chemical and enzymatic degradation in the gastrointestinal tract can lower the amount of active drug available.

Drug Formulation: The physical form of the drug (e.g., tablet, capsule, solution) can affect its dissolution and absorption [2].

Strategies for enhancing bioavailability

1. Formulation approaches

Solid Dispersions

Solid dispersions involve dispersing the poorly soluble drug in a water-soluble carrier matrix. This technique can enhance solubility and dissolution rate.

Lipid-Based Formulations

Incorporating drugs into lipid-based formulations, such as self-emulsifying drug delivery systems (SEDDS), can enhance solubility and absorption, especially for lipophilic drugs.

Nanotechnology

Nanoparticles and nanosuspensions increase surface area and improve dissolution rates. They can also enhance permeability and target drug delivery to specific tissues.

Cyclodextrins

Cyclodextrins are cyclic oligosaccharides that can form inclusion complexes with drugs, enhancing their solubility and stability [3].

2. Chemical modification

Prodrugs

Prodrugs are chemically modified derivatives of the active drug designed to improve solubility, permeability, or stability. The prodrug is converted to the active drug in the body through enzymatic or chemical processes.

Salt Formation

Converting the drug into a more soluble salt form can enhance its dissolution and bioavailability.

3. Permeability enhancers

Permeation Enhancers

These are compounds that temporarily disrupt the integrity of the intestinal epithelium, allowing larger amounts of the drug to pass through.

Bioadhesive Polymers

Polymers that adhere to mucosal surfaces can prolong the residence time of the drug at the absorption site, enhancing absorption [4].

4. Metabolic inhibitors

Enzyme Inhibitors

Co-administration of enzyme inhibitors can reduce the pre-systemic metabolism of drugs, increasing their bioavailability..

Future directions

Research is ongoing to develop novel materials and techniques for bioavailability enhancement. Personalized medicine approaches, leveraging patient-specific data, may further optimize bioavailability strategies, ensuring that patients receive the most effective treatments with minimal adverse effects [5].

Materials and Methods

Materials

Drugs and chemicals:

• Model drugs with varying solubility and permeability characteristics (e.g., Ibuprofen, Curcumin, and Griseofulvin)
• Polymers for solid dispersion (e.g., Polyvinylpyrrolidone (PVP), Hydroxypropyl methylcellulose (HPMC))
• Lipid-based excipients (e.g., Medium-chain triglycerides, Phospholipids)
• Cyclodextrins (e.g., β-cyclodextrin, Hydroxypropyl-β-cyclodextrin)
• Nanoparticle materials (e.g., PLGA, Chitosan)
• Permeation enhancers (e.g., Sodium caprate, Lauryl sulfate)
• Enzyme inhibitors (e.g., Ritonavir, Piperine) [6].

Analytical reagents:

• Solvents for drug dissolution studies (e.g., Phosphate buffer, Simulated gastric fluid)
• High-Performance Liquid Chromatography (HPLC) grade solvents and standards

Equipment:

• High-Performance Liquid Chromatography (HPLC)
• Differential Scanning Calorimetry (DSC)
• Fourier Transform Infrared Spectroscopy (FTIR)
• Dynamic Light Scattering (DLS) for nanoparticle size analysis
• Dissolution apparatus
• Permeability assay setup (e.g., Caco-2 cell lines) [7].

Methods

1. Preparation of formulations

Solid Dispersions:

• Dissolve the drug and polymer in a common solvent.
• Evaporate the solvent under reduced pressure to obtain a solid mass.
• Grind the mass into a fine powder.

Lipid-Based Formulations:

• Dissolve the drug in lipid excipients at an elevated temperature.
• Cool the mixture to form a semi-solid or solid lipid formulation.
• Homogenize the mixture to ensure uniformity.

Nanoparticles:

• Use an emulsion-solvent evaporation method.
• Dissolve the drug and polymer in an organic solvent.
• Emulsify the solution into an aqueous phase containing a surfactant.
• Evaporate the organic solvent under reduced pressure to form nanoparticles.

Cyclodextrin Complexes:

• Mix the drug and cyclodextrin in a suitable solvent.
• Stir the mixture until the complex forms.
• Remove the solvent by freeze-drying or spray-drying [8].

2. Characterization of formulations

Solubility Studies:

Measure drug solubility in water and simulated gastrointestinal fluids using equilibrium solubility methods.

Dissolution Studies:

• Conduct dissolution testing using USP Type II apparatus.
• Measure drug release over time and compare with pure drug and marketed formulations.

Permeability Studies:

• Assess drug permeability using Caco-2 cell monolayers.
• Measure transport across the cell monolayer using HPLC.

Stability Studies:

Evaluate chemical and physical stability of formulations under various conditions (e.g., temperature, humidity).

3. In vivo studies

Animal Models:

• Administer formulations to appropriate animal models (e.g., rats, mice).
• Collect blood samples at various time points.

Pharmacokinetic Analysis:

• Analyze plasma drug concentrations using HPLC.
• Calculate pharmacokinetic parameters (e.g., Cmax, Tmax, AUC) to assess bioavailability [9].

4. Data analysis

Use statistical software to analyze data.

Perform comparative analysis of bioavailability enhancements using different strategies.

Present results in terms of solubility, dissolution rate, permeability, and bioavailability improvements.

This structured approach enables the systematic evaluation of various bioavailability enhancement strategies, providing a comprehensive understanding of their effectiveness in improving drug absorption and therapeutic efficacy [10].

Discussion

Enhancing bioavailability is a pivotal aspect of pharmaceutical development, crucial for optimizing drug efficacy and patient outcomes. This review discussed various strategies employed to overcome challenges such as poor solubility, limited permeability, and extensive first-pass metabolism, which commonly restrict bioavailability.

Formulation strategies

Solid dispersions and lipid-based formulations emerged as effective approaches to enhance solubility and dissolution rates. Solid dispersions utilize carriers like polymers to improve drug dispersibility, while lipid-based formulations enhance drug solubility in lipophilic media, facilitating absorption. Nanotechnology, including nanoparticles and nanosuspensions, offers targeted delivery and improved bioavailability by enhancing drug stability and permeation.

Chemical modifications

Prodrugs and salt formation techniques modify drug properties to enhance solubility and permeability. Prodrugs undergo enzymatic conversion to active forms, minimizing first-pass metabolism, while salt formation alters drug physicochemical properties to improve dissolution and absorption characteristics.

Permeability enhancers

Permeation enhancers and bioadhesive polymers facilitate drug absorption by temporarily altering mucosal permeability or prolonging contact time at absorption sites. These strategies are critical for drugs with low intestinal permeability or high susceptibility to efflux transporters.

Enzyme inhibition

Co-administration of enzyme inhibitors mitigates pre-systemic metabolism, increasing drug bioavailability by preserving the active form during absorption phases. This approach is particularly beneficial for drugs prone to extensive hepatic or intestinal metabolism.

Comparative effectiveness

Comparative studies highlighted the advantages and limitations of each strategy in enhancing bioavailability. Solid dispersions and lipid-based formulations generally improve solubility and dissolution rates but may require optimization for stability and scale-up. Nanotechnology offers precise control over particle size and surface properties, enhancing drug absorption and targeting.

Clinical implications

The translation of enhanced bioavailability strategies into clinical settings holds promise for optimizing therapeutic outcomes. Improved bioavailability reduces dosing frequency, minimizes side effects, and enhances patient compliance. However, the clinical efficacy of these formulations depends on factors such as patient variability, disease state, and formulation stability under physiological conditions.

Challenges and future directions

Despite advancements, challenges remain in achieving consistent and predictable bioavailability enhancement across diverse drug classes and patient populations. Formulation stability, regulatory approval, and cost-effectiveness are critical considerations. Future research may focus on personalized medicine approaches, integrating patient-specific factors to tailor bioavailability enhancement strategies.

Conclusion

Enhancing bioavailability is a critical objective in pharmaceutical development to maximize therapeutic efficacy and patient outcomes. This review comprehensively explored various strategies employed to overcome bioavailability challenges associated with poor solubility, limited permeability, and extensive first-pass metabolism.

Formulation approaches, including solid dispersions, lipid-based formulations, and nanotechnology, have demonstrated significant improvements in drug solubility, dissolution rates, and targeted delivery. These strategies leverage advances in materials science and formulation technologies to enhance drug bioavailability effectively.

Chemical modifications such as prodrugs and salt formation techniques alter drug properties to improve absorption and reduce metabolic degradation, thereby increasing bioavailability. Permeation enhancers and bioadhesive polymers play crucial roles in facilitating drug absorption by modifying mucosal permeability and enhancing drug residence time at absorption sites.

Enzyme inhibition strategies offer a promising avenue to minimize pre-systemic metabolism, preserving drug efficacy during absorption phases. These approaches are particularly advantageous for drugs susceptible to extensive metabolism in the liver or intestine.

Comparative studies highlighted the efficacy and limitations of each bioavailability enhancement strategy, emphasizing the need for tailored approaches based on drug characteristics and patient-specific factors. Clinical implications include improved therapeutic outcomes, reduced dosing frequency, and enhanced patient compliance, contributing to better treatment adherence and efficacy.

Challenges remain in scaling up formulations, ensuring stability, and navigating regulatory requirements for clinical application. Future research directions may explore personalized medicine approaches to optimize bioavailability enhancement strategies based on individual patient profiles and disease states.

References

1. Langer R, Weissleder R (2015) Scientific discovery and the future of medicine. JAMA 313: 135-136.

Indexed at, Google Scholar, Crossref

2. Coccia M, Wang L (2015) Path-breaking directions of nanotechnology-based chemotherapy and molecular cancer therapy. Technol Forecast Soc Change 94: 155-169.

Google Scholar

3. Farokhzad OC, Langer R (2006) Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Del Rev 58: 1456-1459.

Indexed at, Google Scholar, Crossref

4. Sayes CM, Aquino GV, Hickey AJ (2017) Nanomaterial drug products: manufacturing and analytical perspectives. AAPS J 19: 18-25.

Indexed at, Google Scholar, Crossref

5. Dilnawaz F, Acharya S, Sahoo SK (2018) Recent trends of nanomedicinal approaches in clinics. Int J Pharm 538: 263-278.

Indexed at, Google Scholar, Crossref

6. Ragelle H, Danhier F, Préat V, Langer R, Anderson DG (2017) Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures. Expert Opin Drug Deliv 14: 851-864.

Indexed at, Google Scholar, Crossref

7. Bertilsson L, Dengler HJ, Eichelbaum M (1980) Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur J Clin Pharmacol 17: 153-155.

Indexed at, Google Scholar, Crossref

8. Beutler E, Gelbart T, Demina A (1998) Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 95: 8170-8174.

Indexed at, Google Scholar, Crossref

9. Carson PE, Flanagan CL, Ickes CE (1956) Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 124: 484-485.

Indexed at, Google Scholar, Crossref

10. Chowbay B, Li H, David M (2005) Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 60: 159-171.

Indexed at, Google Scholar, Crossref